ESTAZOLAM

Details

Stereochemistry	ACHIRAL
Molecular Formula	C16H11ClN4
Molecular Weight	294.738
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

ClC1=CC=C2N3C=NN=C3CN=C(C4=CC=CC=C4)C2=C1

InChI

InChIKey=CDCHDCWJMGXXRH-UHFFFAOYSA-N

InChI=1S/C16H11ClN4/c17-12-6-7-14-13(8-12)16(11-4-2-1-3-5-11)18-9-15-20-19-10-21(14)15/h1-8,10H,9H2

HIDE SMILES / InChI

Molecular Formula	C16H11ClN4
Molecular Weight	294.738
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.drugbank.ca/drugs/DB01215
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/estazolam.html

Estazolam, a triazolobenzodiazepine derivative, is an oral hypnotic agent with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than diazepam or nitrazepam. Benzodiazepines bind nonspecifically to benzodiazepine receptors, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects GABA by increasing GABA affinity for the GABA receptor. Binding of the inhibitory neurotransmitter GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell. Used for the short-term management of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. Marketed under the brand names ProSom, Eurodin.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
GABA-A receptor; anion channel 203 Target ID: CHEMBL2093872 Sources: http://www.drugbank.ca/drugs/DB01215	Agonist 2752
platelet aggregation 80 Target ID: GO:0070527 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2890779	Inhibitor 8504		3.8 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Insomnia 111 Sources: https://www.drugs.com/dosage/estazolam.html	Primary		Approved 8583	Estazolam Approved Use Estazolam is indicated for the short-term management of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. Launch Date 1997

C_max

Value	Dose	Analyte	Population
54.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1968715/	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	ESTAZOLAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
98.6 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1968715/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	ESTAZOLAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
194 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2862746/	4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered:	ESTAZOLAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
180 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2862746/	2 mg 2 times / day steady-state, oral dose: 2 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ESTAZOLAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
1050 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1968715/	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	ESTAZOLAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2060 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1968715/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	ESTAZOLAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4343 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2862746/	4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered:	ESTAZOLAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
5517 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2862746/	2 mg 2 times / day steady-state, oral dose: 2 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ESTAZOLAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
14.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1968715/	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	ESTAZOLAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
14.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1968715/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	ESTAZOLAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
19 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2862746/	4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered:	ESTAZOLAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
17 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2862746/	2 mg 2 times / day steady-state, oral dose: 2 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ESTAZOLAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
6 mg 1 times / day single, oral Highest studied dose Dose: 6 mg, 1 times / day Route: oral Route: single Dose: 6 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1972381/	healthy, 21-47 Health Status: healthy Age Group: 21-47 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/1972381/	Sources: https://pubmed.ncbi.nlm.nih.gov/1972381/
2 mg 1 times / day multiple, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: multiple Dose: 2 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1968713/	unhealthy, 42.9 (18-85) Health Status: unhealthy Age Group: 42.9 (18-85) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/1968713/	Disc. AE: Illness, Somnolence... AEs leading to discontinuation/dose reduction: Illness Somnolence (grade 1-2) Dizziness (grade 1-2) Sources: https://pubmed.ncbi.nlm.nih.gov/1968713/
40 mg 1 times / day single, oral Overdose Dose: 40 mg, 1 times / day Route: oral Route: single Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/anda/97/74826ap.pdf	unknown, unknown Health Status: unknown Age Group: unknown Sex: unknown Sources: https://www.accessdata.fda.gov/drugsatfda_docs/anda/97/74826ap.pdf	Disc. AE: Somnolence, Respiratory depression... AEs leading to discontinuation/dose reduction: Somnolence Respiratory depression Confusion Coordination impaired Slurred speech Coma Sources: https://www.accessdata.fda.gov/drugsatfda_docs/anda/97/74826ap.pdf

AEs

AE	Significance	Dose	Population
Illness	Disc. AE	2 mg 1 times / day multiple, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: multiple Dose: 2 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1968713/	unhealthy, 42.9 (18-85) Health Status: unhealthy Age Group: 42.9 (18-85) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/1968713/
Dizziness	grade 1-2 Disc. AE	2 mg 1 times / day multiple, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: multiple Dose: 2 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1968713/	unhealthy, 42.9 (18-85) Health Status: unhealthy Age Group: 42.9 (18-85) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/1968713/
Somnolence	grade 1-2 Disc. AE	2 mg 1 times / day multiple, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: multiple Dose: 2 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1968713/	unhealthy, 42.9 (18-85) Health Status: unhealthy Age Group: 42.9 (18-85) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/1968713/
Coma	Disc. AE	40 mg 1 times / day single, oral Overdose Dose: 40 mg, 1 times / day Route: oral Route: single Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/anda/97/74826ap.pdf	unknown, unknown Health Status: unknown Age Group: unknown Sex: unknown Sources: https://www.accessdata.fda.gov/drugsatfda_docs/anda/97/74826ap.pdf
Confusion	Disc. AE	40 mg 1 times / day single, oral Overdose Dose: 40 mg, 1 times / day Route: oral Route: single Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/anda/97/74826ap.pdf	unknown, unknown Health Status: unknown Age Group: unknown Sex: unknown Sources: https://www.accessdata.fda.gov/drugsatfda_docs/anda/97/74826ap.pdf
Coordination impaired	Disc. AE	40 mg 1 times / day single, oral Overdose Dose: 40 mg, 1 times / day Route: oral Route: single Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/anda/97/74826ap.pdf	unknown, unknown Health Status: unknown Age Group: unknown Sex: unknown Sources: https://www.accessdata.fda.gov/drugsatfda_docs/anda/97/74826ap.pdf
Respiratory depression	Disc. AE	40 mg 1 times / day single, oral Overdose Dose: 40 mg, 1 times / day Route: oral Route: single Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/anda/97/74826ap.pdf	unknown, unknown Health Status: unknown Age Group: unknown Sex: unknown Sources: https://www.accessdata.fda.gov/drugsatfda_docs/anda/97/74826ap.pdf
Slurred speech	Disc. AE	40 mg 1 times / day single, oral Overdose Dose: 40 mg, 1 times / day Route: oral Route: single Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/anda/97/74826ap.pdf	unknown, unknown Health Status: unknown Age Group: unknown Sex: unknown Sources: https://www.accessdata.fda.gov/drugsatfda_docs/anda/97/74826ap.pdf
Somnolence	Disc. AE	40 mg 1 times / day single, oral Overdose Dose: 40 mg, 1 times / day Route: oral Route: single Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/anda/97/74826ap.pdf	unknown, unknown Health Status: unknown Age Group: unknown Sex: unknown Sources: https://www.accessdata.fda.gov/drugsatfda_docs/anda/97/74826ap.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946 inducer 1087	substrate 1193 inhibitor 2438	substrate 1388 inhibitor 2507

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 CYP2A6 879 CYP2C19 2057 CYP2E1 1060 CYP3A 227 OATP1B1/3 12 OCT1 620	CYP1A2 1197 CYP2A6 626 CYP2C19 1119 CYP2E1 729	CYP1A2 832 CYP2B6 669 OCT1 39 P-gp 301 MRP2 146 MRP3 83 BCRP 101 OATP1B1 29

Drug as perpetrator

Target	Modality	Activity
BCRP 985	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/25183402/	no
CYP1A2 2333	inhibitor 4027 Sources: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a1e3b4bf-22e9-430a-a768-4d86ae886c9e	no
CYP2A6 911	inhibitor 4027 Sources: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a1e3b4bf-22e9-430a-a768-4d86ae886c9e	no
CYP2B6 1160	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/25183402/	no
CYP2C19 2141	inhibitor 4027 Sources: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a1e3b4bf-22e9-430a-a768-4d86ae886c9e	no
CYP2C9 2497	inhibitor 4027 Sources: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a1e3b4bf-22e9-430a-a768-4d86ae886c9e	no
CYP2D6 2546	inhibitor 4027 Sources: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a1e3b4bf-22e9-430a-a768-4d86ae886c9e	no
CYP2E1 1146	inhibitor 4027 Sources: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a1e3b4bf-22e9-430a-a768-4d86ae886c9e	no
CYP3A 317	inhibitor 4027 Sources: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a1e3b4bf-22e9-430a-a768-4d86ae886c9e	no
CYP3A4 2633	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/25183402/	no
MRP2 625	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/25183402/	no
MRP3 326	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/25183402/	no
OATP1B1 1095	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/25183402/	no
OCT1 656	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/25183402/	no
P-gp 1932	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/25183402/	no
OATP1B1/3 12	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/20381614/	yes [Inhibition 10 uM]
OCT1 656	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/20381614/	yes [Inhibition 10 uM]
CYP1A2 2333	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/25183402/	yes

Drug as victim

Target	Modality	Activity
CYP1A2 1197	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/16012077/	no
CYP2A6 626	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/16012077/	no
CYP2C19 1119	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/16012077/	no
CYP2C9 1193	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/16012077/	no
CYP2D6 1388	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/16012077/	no
CYP2E1 729	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/16012077/	no
CYP3A4 1946	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/16012077/	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:4858	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:4858
eMolecules	538014	https://www.emolecules.com/cgi-bin/more?vid=538014
ZINC	ZINC000000001370	http://zinc15.docking.org/substances/ZINC000000001370

PubMed

Title	Date	PubMed
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.	2010-12	21818443
A validated method for simultaneous screening and quantification of twenty-three benzodiazepines and metabolites plus zopiclone and zaleplone in whole blood by liquid-liquid extraction and ultra-performance liquid chromatography- tandem mass spectrometry.	2010-07-29	20663286
Management of tinea capitis in childhood.	2010-07-14	21437064
5-(4-Chloro-phen-yl)-3-(2,4-dimethyl-thiazol-5-yl)-1,2,4-triazolo[3,4-a]isoquinoline.	2010-04-10	21579114
[The influence of estazolam on human neurobehavioral function].	2010-02	20232740
[Clinical observation on acupoint catgut embedding at head-acupoint combined with massage of sole for treatment of refractory insomnia].	2010-02	20214068
Four cases of dysthymic disorder and general malaise successfully treated with traditional herbal (kampo) medicines: kamiuntanto.	2010	21614161
Algorithms for the assessment and management of insomnia in primary care.	2009-11-03	19936140
Drugs associated with more suicidal ideations are also associated with more suicide attempts.	2009-10-02	19798416
The XIA's No. 1 sleeping Prescription for the treatment of insomnia of the deficiency type: a clinical observation of 60 cases.	2009-09	19894388
[Simultaneous determination of 5 sedative hypnotics in human plasma by reversed phase high-performance liquid chromatography].	2009-07	19648689
Forty cases of insomnia treated by suspended moxibustion at Baihui (GV 20).	2009-06	19663092
Simultaneous determination of benzodiazepines and their metabolites in human serum by liquid chromatography-tandem mass spectrometry using a high-resolution octadecyl silica column compatible with aqueous compounds.	2009-04	18937304
[Effect of modified xiaoyao powder for improving sleep in patients with psychological stress insomnia].	2009-03	19548434
[Analysis on somnipathy related factors in elderly patients with stroke and comparative study on the efficacy of treatment by traditional Chinese medicine and by estazolam].	2009-03	19548433
Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders.	2009	19228178
Auricular acupuncture for insomnia: a systematic review.	2008-11	18754807
High performance liquid chromatography-tandem mass spectrometric determination of rupatadine in human plasma and its pharmacokinetics.	2008-08-05	18472381
Simultaneous determination of naringenin and hesperetin in rats after oral administration of Da-Cheng-Qi decoction by high-performance liquid chromatography-tandem mass spectrometry.	2008-07	18384064
Long-term stability of various drugs and metabolites in urine, and preventive measures against their decomposition with special attention to filtration sterilization.	2008-01-30	17555899
Comparative bioavailability of two estazolam tablet formulations in Indonesian healthy volunteers.	2008	19025059
Abdominal acupuncture for insomnia in women: a randomized controlled clinical trial.	2008	18672743
Indiplon in the treatment of sleep disorders.	2007-12	19300612
[Randomized and controlled study on effect of acupuncture on sleep quality in the patient of primary insomnia].	2007-12	18271228
Sensitive and selective liquid chromatography-tandem mass spectrometry method for the quantification of aniracetam in human plasma.	2007-10-15	17826366
High performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI) method for simultaneous determination of venlafaxine and its three metabolites in human plasma.	2007-05-01	17222591
[Comparative study on treatment of somnipathy in patients with hypertension by traditional Chinese medicine and by estazolam].	2007-02	17342998
Determination of four benzodiazepine residues in pork using multiwalled carbon nanotube solid-phase extraction and gas chromatography-mass spectrometry.	2006-12-08	17054968
[Analysis of 37 drugs in whole blood by HPLC after solid phase extraction].	2006-10-15	17190147
[Effects of midazolam and estazolam as hypnotics in hypertensive patients with chronic insomnia: a multicentre, open labeled, randomized clinical trial].	2006-04	16776928
Simultaneous determination of spironolactone and its active metabolite canrenone in human plasma by HPLC-APCI-MS.	2006-04	16541392
Sleep maintenance insomnia: strengths and weaknesses of current pharmacologic therapies.	2006-03-07	16517453
High-performance liquid chromatography-atmospheric pressure chemical ionisation-mass spectrometry determination of zaleplon in human plasma.	2006-02-24	16087308
Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality.	2005-12	18360572
Design and synthesis of new 2-substituted-5-(2-benzylthiophenyl)-1,3,4-oxadiazoles as benzodiazepine receptor agonists.	2005-06-15	15876530
Prediction of genotoxicity of chemical compounds by statistical learning methods.	2005-06	15962942
Identification of human cytochrome P450 enzymes involved in the formation of 4-hydroxyestazolam from estazolam.	2005-05	16012077
TCM treatment for 63 cases of senile dyssomnia.	2005-03	15889523
Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds.	2005	16336040
Date-rape drugs scene in Poland.	2005	16225127
Simultaneous determination of albendazole and its major active metabolite in human plasma using a sensitive and specific liquid chromatographic-tandem mass spectrometric method.	2004-06-29	15193727
Overview of the therapeutic management of insomnia with zolpidem.	2004	15291010
Pharmacokinetics and drug interactions of the sedative hypnotics.	2003	14561946
Simultaneous analyses of hypoglycemic agents and C-peptide are essential in a homicide case with the combined dosing insulin and insulin-releasing drug.	2002-03	12935689
Metabolic alkalosis and myoclonus from antacid ingestion.	1996-06	8835608
Estazolam treatment of insomnia in generalized anxiety disorder: a placebo-controlled study.	1991-08	1918423
Inhibition of the binding and the behavioral effects of thyrotropin-releasing hormone (TRH) by the triazolobenzodiazepines.	1988-05	2845442
[Electroencephalographic effects of 450191-S and its metabolites in rabbits with chronic electrode implants].	1986-07	3758874
Comparative efficacy of estazolam, flurazepam, and placebo in outpatients with insomnia.	1986-07	2873132
Diazepam-induced decrease in histamine turnover in mouse brain.	1986-05-27	3089825

Patents

Sample Use Guides

In Vivo Use Guide

Usual Adult Dose for Insomnia 1 to 2 mg orally at bedtime

Route of Administration: Oral

In Vitro Use Guide

Incubation of rabbit PRP with etizolam for 2 min before administration of aggregating agents inhibited aggregation induced by PAF (190 nM) with an IC50 of 3.8 uM. Etizolam at a higher concentration (300 uM) only slightly in hibited ADP (15 uM) and arachidonic acid-induced aggregation

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:56:07 GMT 2025` Edited by `admin` on `Mon Mar 31 17:56:07 GMT 2025`
Record UNII	36S3EQV54C
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ESTAZOLAM CIV

Preferred Name

English

ESTAZOLAM

Official Name

English

NSC-290818

Code

English

ESTAZOLAM [USAN]

Common Name

English

ABBOTT-47631

Code

English

ESTAZOLAM [VANDF]

Common Name

English

ESTAZOLAM [IARC]

Common Name

English

ESTAZOLAM [USP MONOGRAPH]

Common Name

English

ESTAZOLAM [MI]

Common Name

English

Estazolam [WHO-DD]

Common Name

English

ESTAZOLAM CIV [USP-RS]

Common Name

English

ESTAZOLAM [JAN]

Common Name

English

8-Chloro-6-phenyl-4H-S-triazolo[4,3-a][1,4]benzodiazepine

Systematic Name

English

4H-(1,2,4)TRIAZOLO(4,3-A)(1,4)BENZODIAZEPINE, 8-CHLORO-6-PHENYL-

Systematic Name

English

ESTAZOLAM [MART.]

Common Name

English

estazolam [INN]

Common Name

English

PROSOM

Brand Name

English

ESTAZOLAM [ORANGE BOOK]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1012